REHOVOT, Israel, Dec. 21, 2022 /PRNewswire/ – This poster was shown at the recent ESMO immuno-oncology Congress in Geneva The cResponse platform can also be used to model and evaluate immune modulating drugs within cancer tissue. The cResponse test maintains high viability in human cancer. This allows for the preservation of the 3D architecture and its microenvironment. This is essential to evaluate the Immuno-oncology response. This data shows that T-Cells can be activated and cancer tissue recruited when stimulated with an immuno-oncology agent in colorectal and lung cancer.
Curesponse A commercial-stage precision oncology company, it is the creator of the cResponse Platform, an AI-driven, functional genomic drug prioritization technology.
“We are proud that we presented results using our technology using an Immuno-oncology compounds at the largest Immuno-Oncology Conference in EuropeDr. Vered bar, VP R&D of Curesponse . “Modeling immunotherapy responses is essential for the development and targeting of cancer therapies that are more precise. Our combined genomic-functional platform is already being used by many cancer researchers worldwide. We look forward to extending the platform to other cancer researchers as well to our pharmaceutical partners.
The cResponse platform integrates next-generation sequencing (NGS), a proprietary functional assay, and a method that determines the cancerous tissue’s response to drug combinations. This preserves the Tumor Microenvironment (TME). This allows cResponse, the world’s premier platform, to offer patients, oncologists and pharma partners an empirical test that captures the specificity and resistance of a tumor to various drugs and combinations within two weeks of tissue sampling. The technology is applicable to all therapeutic modality options, including targeted therapy, chemotherapy, and, as in this case, immuno-therapy.
The company has partnered with top pharma partners to offer cResponse, a faster and more predictive platform for drug development. The cResponse testing is CE-marked and routinely reimbursed in private payers. Israel for personalized cancer treatment decision guidance. Patients in the UK and EU with H1 2023 will have the opportunity to take the test. USA In 2024.
Contact us for more information [email protected]